

Manuscript Number:

Title: Author's reply: Fructose, uric acid and zonal differences in NASH

Article Type: Letter to the Editor

Corresponding Author: Dr. Valerio Nobili,

Corresponding Author's Institution: Bambino Gesù Hospital

First Author: Valerio Nobili

Order of Authors: Valerio Nobili; Antonella Mosca; Eleonora Scorletti;
Christopher D Byrne

Author's reply: Fructose, uric acid and zonal differences in NASH

Nobili V¹, Mosca A¹, Scorletti E², Byrne CD²

- 1. Hepatometabolic Unit - Bambino Gesù Children's Hospital, Rome, Italy.
- 2. Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom; NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton, United Kingdom

Correspondence to: Valerio Nobili, MD,
Head of Hepato-Metabolic Disease Unit, “Bambino Gesù” Children’s Hospital IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), P.le S. Onofrio, 4 – 00165, Rome, Italy, Phone/Fax: +39-06-68592192, e-mail: valerio.nobili@opbg.net

Funding: This study did not receive funding.
Conflict of interest: The authors have no conflicts of interest to declare.

Author contributions: AM and SE were all manuscript drafting, NV and BCD have revised the final manuscript.

Keywords: fructose, uric acid, non-alcoholic steatohepatitis, children

Word count: 625

Number of tables: 0; **number of figures:** 0

Author's reply: Fructose, uric acid and zonal differences in NASH

Nobili V¹, Mosca A¹, Scorletti E², Byrne CD²

¹. Hepatometabolic Unit - Bambino Gesù Children's Hospital, Rome, Italy.

². Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom; NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton, United Kingdom

Refers to: Mann J.P., Armstrong M.J. “Fructose, uric acid, and zonal differences in NASH”

Dear Editor,

We read with interest the letter by Mann & Armstrong, referring to our article entitled “Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents” [1,2]. The liver has a unique dual blood supply receiving both arterial blood and blood from the portal vein. This phenomenon and the liver cellular architecture results in hepatocytes being exposed to differential oxygen tensions and varying concentrations of dietary nutrients, according to their position across the liver lobule. Venous blood from the portal vein mixes with arterial blood from the hepatic artery in the periportal zone of the liver (where biliary ductules are also located), so that hepatocytes in this region are exposed to a higher oxygen tension, and receive blood that is rich in dietary nutrients [3]. In contrast, perivenous hepatocytes are exposed to a lower oxygen tension and lower concentrations of dietary nutrients, because blood flows along the sinuses from the periportal region towards the central veins which are located in the perivenous zones. As a consequence of this unique blood supply, metabolic functions in lobular

1 hepatocytes vary, dependent on the position of any given hepatocyte in the liver lobule [4]. For
2 example, in the periportal zone, where oxygen tension is highest, levels of β -oxidation in
3
4 hepatocytes is also highest, because this metabolic activity requires high oxygen tension.
5
6
7
8

9 In their letter, Mann & Armstrong suggest that high fructose exposure should cause hepatic zonal
10 injury and features of non alcoholic steatohepatitis (NASH), specifically in the perivenous zone [1].
11
12 The authors assert that fructose (and alcohol) should induce a perivenous pattern of steatosis and
13
14 inflammation by increasing *de novo* lipogenesis and oxidative stress in this region. However, we
15
16 reason that if there is fructose-induced differential damage to hepatocytes across the liver lobule; in
17
18 our opinion, the detrimental influence of fructose should be greatest in hepatocytes in the periportal
19
20 region. This is because, hepatocytes in the periportal zone would receive the highest concentrations
21
22 of fructose via the portal vein. Consequently, we would expect a periportal pattern of development of
23
24 inflammation and fibrosis occurring in this zone, induced by generation of free radicals (as oxygen
25
26 tension is also highest in this zone). As stated above, the concentration of oxygen decreases along a
27
28 gradient from the periportal to the perivenous zone of the liver lobule. Based on a reduced oxygen
29
30 tension in the perivenous region, high levels of cytosolic triglyceride synthesis occurs in
31
32 hepatocytes in this zone, since lower oxygen tension does not affect this metabolic function. Thus,
33
34 we reason that we might also expect increased levels of *de novo* lipogenesis, (induced by fructose
35
36 stimulation of lipogenesis in hepatocytes) in the perivenous zone, but without inflammation or
37
38 fibrosis, because the oxygen tension is low in this zone.
39
40
41
42
43
44
45
46
47
48
49
50

51 That said, regardless of who is correct, the hypothesis of differential zonal injury induced by high
52
53 levels of dietary fructose consumption, proposed by Mann & Armstrong, is very interesting. To
54
55 date, we have not defined the pattern of zonal injury associated with high levels of dietary fructose
56
57 consumption and hyperuricaemia in this cohort. However, in our population of 271 biopsy-proven
58
59 NAFLD patients, a positive correlation was observed between fructose consumption and portal
60
61
62
63
64
65

inflammation ($r = 0.19$, $p = 0.05$), fibrosis ($r = 0.27$, $p < 0.001$) and between fructose consumption and steatosis ($r = 0.32$, $p < 0.001$). No significant correlations were noted between fructose consumption and ballooning of hepatocytes or lobular inflammation were observed.

We suggest that further study is needed to elucidate the relationships between specific pathogenetic stimuli and patterns of zonal injury in NAFLD. Such study may give better insight into why NAFLD progresses in some patients to serious end stage liver disease or hepatocellular carcinoma, and in other patients the liver condition remains relatively quiescent.

References

1. Mann JP, Armstrong MJ. Fructose, uric acid, and zonal differences in NASH. J Hepatol 2017.
2. Mosca A, Nobili V, De Vito R, Crudele A, Scorletti E, Villani A, et al. Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents. J Hepatol 2017;66:1031–6. doi:10.1016/j.jhep.2016.12.025.
3. Colnot S, Perret C. Chapter 2: Liver zonation in Monga S. Molecular Pathology of Liver Diseases. Springer ed., 2010.
4. Jungermann K, Kietzmann T. Zonation of parenchymal and nonparenchymal metabolism in liver. Annu Rev Nutr. 1996;16:179–203.